Exogenous estrogen and endometrial carcinoma: case-control and incidence study

Area of Science:

• Gynecology
• Oncology
• Epidemiology

Background:

• Previous studies suggested a link between exogenous estrogen and endometrial cancer risk.
• The specific impact of conjugated estrogens on endometrial cancer incidence required further investigation.

Purpose of the Study:

• To assess the association between conjugated estrogen use and endometrial cancer risk.
• To evaluate the effect of conjugated estrogen therapy duration, dosage, and administration on endometrial cancer incidence.

Main Methods:

• A case-control study was conducted in Olmsted County, Minnesota, from 1945-1974.
• 145 endometrial cancer patients were matched with four controls each.
• Data on exogenous estrogen exposure, including conjugated estrogens, was collected and analyzed.

Main Results:

• Conjugated estrogen treatment for 6 months or longer was associated with a 4.9-fold increased risk (P < 0.01).
• Exposure for 3 years or longer showed a relative risk of 7.9 (P < 0.01).
• Increased risk correlated with higher doses (≥1.25 mg) and continuous administration.

Conclusions:

• Conjugated estrogen therapy is a significant risk factor for endometrial cancer.
• Despite increased individual risk, the overall incidence of endometrial cancer in the region remained constant due to low usage rates.